Skip to main content

Advertisement

SpringerLink
Log in

FDG PET/CT imaging as a biomarker in lymphoma

  • Review Article
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

Abstract

FDG PET/CT has changed the management of FDG-avid lymphoma and is now recommended as the imaging technique of choice for staging and restaging. The need for tailoring therapy to reduce toxicity in patients with a favourable outcome and for improving treatment in those with high-risk factors requires accurate diagnostic methods and a new prognostic algorithm to identify different risk categories. New drugs are used in relapsed/refractory patients. The role of FDG PET/CT as a biomarker in this context is summarized in this review. New trends in FDG metabolic imaging in lymphoma are addressed including metabolic tumour volume measurement at staging and integrative PET which combines PET data with clinical and molecular markers or other imaging techniques. The quantitative approach for response assessment which is under investigation and is used in large ongoing trials is compared with visual criteria. The place of FDG in the era of targeted therapy is discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Moccia AA, Donaldson J, Chhanabhai M, Hoskins PJ, Klasa RJ, Savage KJ, et al. International Prognostic Score in advanced-stage Hodgkin’s lymphoma: altered utility in the modern era. J Clin Oncol. 2012;30:3383–8.

    Article  PubMed  Google Scholar 

  2. Canellos GP, Rosenberg SA, Friedberg JW, Lister TA, Devita VT. Treatment of Hodgkin lymphoma: a 50-year perspective. J Clin Oncol. 2014;32:163–8.

    Article  CAS  PubMed  Google Scholar 

  3. Vaidya R, Witzig TE. Prognostic factors for diffuse large B-cell lymphoma in the R(X)CHOP era. Ann Oncol. 2014;25:2124–33.

    Article  CAS  PubMed  Google Scholar 

  4. Trotman J, Fournier M, Lamy T, Seymour JF, Sonet A, Janikova A, et al. Positron emission tomography-computed tomography (PET-CT) after induction therapy is highly predictive of patient outcome in follicular lymphoma: analysis of PET-CT in a subset of PRIMA trial participants. J Clin Oncol. 2011;29:3194–200.

    Article  PubMed  Google Scholar 

  5. Federico M, Bellei M, Marcheselli L, Luminari S, Lopez-Guillermo A, Vitolo U, et al. Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol. 2009;27:4555–62.

    Article  PubMed  Google Scholar 

  6. Barrington SF, Mikhaeel NG, Kostakoglu L, Meignan M, Hutchings M, Müeller SP, et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol. 2014;32:3048–58.

    Article  PubMed  Google Scholar 

  7. Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Lister TA, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32:3059–68.

    Article  PubMed  Google Scholar 

  8. Steidl C, Connors JM, Gascoyne RD. Molecular pathogenesis of Hodgkin’s lymphoma: increasing evidence of the importance of the microenvironment. J Clin Oncol. 2011;29:1812–26.

    Article  CAS  PubMed  Google Scholar 

  9. Gallamini A. Positron emission tomography scanning: a new paradigm for the management of Hodgkin’s lymphoma. Haematologica. 2010;95:1046–8.

    Article  PubMed Central  PubMed  Google Scholar 

  10. Hartmann S, Agostinelli C, Diener J, Döring C, Fanti S, Zinzani PL, et al. GLUT1 expression patterns in different Hodgkin lymphoma subtypes and progressively transformed germinal centers. BMC Cancer. 2012;12:586.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  11. Schoder H, Noy A, Gonen M, Weng L, Green D, Erdi YE, et al. Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin’s lymphoma. J Clin Oncol. 2005;23:4643–51.

    Article  PubMed  Google Scholar 

  12. Bodet-Milin C, Kraeber-Bodere F, Moreau P, Campion L, Dupas B, Le Gouill S. Investigation of FDG-PET/CT imaging to guide biopsies in the detection of histological transformation of indolent lymphoma. Haematologica. 2008;93:471–2.

    Article  PubMed  Google Scholar 

  13. Karam M, Ata A, Irish K, Feustel PJ, Mottaghy FM, Stroobants SG, et al. FDG positron emission tomography/computed tomography scan may identify mantle cell lymphoma patients with unusually favorable outcome. Nucl Med Commun. 2009;30:770–8.

    Article  PubMed  Google Scholar 

  14. Bodet-Milin C, Touzeau C, Leux C, Sahin M, Moreau A, Maisonneuve H, et al. Prognostic impact of 18F-fluoro-deoxyglucose positron emission tomography in untreated mantle cell lymphoma: a retrospective study from the GOELAMS group. Eur J Nucl Med Mol Imaging. 2010;37:1633–42.

    Article  CAS  PubMed  Google Scholar 

  15. Trotman JL, Dupuis J, Meignan M. Quantitative pre-treatment PET in follicular lymphoma. Presented at the Fifth International Workshop on PET in Lymphoma, Menton, 19–20 September 2014. http://www.lyphomapet.com.

  16. Gallicchio R, Mansueto G, Simeon V, Nardelli A, Guariglia R, Capacchione D, et al. F-18 FDG PET/CT quantization parameters as predictors of outcome in patients with diffuse large B-cell lymphoma. Eur J Haematol. 2014;92:382–9.

    Article  CAS  PubMed  Google Scholar 

  17. Eichenauer DA, Engert A, André M, Federico M, Illidge T, Hutchings M, Ladetto M, ESMO Guidelines Working Group. Hodgkin's lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25:Suppl 3:iii70–5.

  18. Pfreundschuh M, Ho AD, Cavallin-Stahl E, Wolf M, Pettengell R, Vasova I, et al. Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study. Lancet Oncol. 2008;9:435–44.

    Article  PubMed  Google Scholar 

  19. Pfreundschuh M, Kuhnt E, Trumper L, Osterborg A, Trneny M, Shepherd L, et al. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol. 2011;12:1013–22.

    Article  CAS  PubMed  Google Scholar 

  20. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin’s disease. International Prognostic Factors Project on Advanced Hodgkin’s Disease. N Engl J Med. 1998;339:1506–14.

    Article  CAS  PubMed  Google Scholar 

  21. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235–42.

    Article  CAS  PubMed  Google Scholar 

  22. Gobbi PG, Bassi E, Bergonzi M, Merli F, Coriani C, Iannitto E, et al. Tumour burden predicts treatment resistance in patients with early unfavourable or advanced stage Hodgkin lymphoma treated with ABVD and radiotherapy. Hematol Oncol. 2012;30:194–9.

    Article  PubMed  Google Scholar 

  23. Meignan M, Sasanelli M, Casasnovas RO, Luminari S, Fioroni F, Coriani C, et al. Metabolic tumour volumes measured at staging in lymphoma: methodological evaluation on phantom experiments and patients. Eur J Nucl Med Mol Imaging. 2014;41:1113–22.

    Article  CAS  PubMed  Google Scholar 

  24. Kanoun S, Rossi C, Berriolo-Riedinger A, Dygai-Cochet I, Cochet A, Humbert O, et al. Baseline metabolic tumour volume is an independent prognostic factor in Hodgkin lymphoma. Eur J Nucl Med Mol Imaging. 2014;41:1735–43.

    Article  PubMed  Google Scholar 

  25. Sasanelli M, Meignan M, Haioun C, Berriolo-Riedinger A, Casasnovas RO, Biggi A, et al. Pretherapy metabolic tumour volume is an independent predictor of outcome in patients with diffuse large B-cell lymphoma. Eur J Nucl Med Mol Imaging. 2014;41:2017–22.

    Article  CAS  PubMed  Google Scholar 

  26. Meignan M. Baseline metabolic tumour volume in Hodgkin lymphoma: the prognostic value of accessory cells. Eur J Nucl Med Mol Imaging. 2014;41:1732–4.

    Article  PubMed  Google Scholar 

  27. Cottereau A, Becker S, Itti E, Haioun C, Vera P, Meignan M, Tilly H. Prognostic value of metabolic tumor volume measured on 18F-FDG PET/CT in patients with nodal presentation T-cell lymphoma. Eur J Nucl Med Mol Imaging. 2014;41(2 Suppl):P538.

    Google Scholar 

  28. Mikhaeel NG, Smith D, Philips MM, Dunn JT, Fields PA, Moller H, et al. Does quantitative PET-CT predict prognosis in diffuse large B cell lymphoma. Hematol Oncol. 2013;31 Suppl 1:96–150.

    Google Scholar 

  29. Song MK, Chung JS, Shin HJ, Lee SM, Lee SE, Lee HS, et al. Clinical significance of metabolic tumor volume by PET/CT in stages II and III of diffuse large B cell lymphoma without extranodal site involvement. Ann Hematol. 2012;91:697–703.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  30. Casasnovas RO, Sasanelli M, Berriolo-Riedinger A, Morschhauser F, Itti E, Huglo D, et al. Baseline metabolic tumor volume is predictive of patient outcome in diffuse large B cell lymphoma. Blood (ASH Meeting Abstracts). 2012;120:1598.

    Google Scholar 

  31. Esfahani SA, Heidari P, Halpern EF, Hochberg EP, Palmer EL, Mahmood U. Baseline total lesion glycolysis measured with (18)F-FDG PET/CT as a predictor of progression-free survival in diffuse large B-cell lymphoma: a pilot study. Am J Nucl Med Mol Imaging. 2013;3:272–81.

    PubMed Central  CAS  PubMed  Google Scholar 

  32. Kim TM, Paeng JC, Chun IK, Keam B, Jeon YK, Lee SH, et al. Total lesion glycolysis in positron emission tomography is a better predictor of outcome than the International Prognostic Index for patients with diffuse large B cell lymphoma. Cancer. 2013;119:1195–202.

    Article  CAS  PubMed  Google Scholar 

  33. Meignan M, Gallamini A, Meignan M, Gallamini A, Haioun C. Report on the First International Workshop on Interim-PET-Scan in Lymphoma. Leuk Lymphoma. 2009;50:1257–60.

    Article  PubMed  Google Scholar 

  34. Meignan M, Gallamini A, Itti E, Barrington S, Haioun C, Polliack A. Report on the Third International Workshop on Interim Positron Emission Tomography in Lymphoma held in Menton, France, 26-27 September 2011 and Menton 2011 consensus. Leuk Lymphoma. 2012;53:1876–81.

    Article  PubMed  Google Scholar 

  35. Juweid ME, Stroobants S, Hoekstra OS, Mottaghy FM, Dietlein M, Guermazi A, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol. 2007;25:571–8.

    Article  PubMed  Google Scholar 

  36. Gallamini A, Hutchings M, Rigacci L, Specht L, Merli F, Hansen M, et al. Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin’s lymphoma: a report from a joint Italian-Danish study. J Clin Oncol. 2007;25:3746–52.

    Article  CAS  PubMed  Google Scholar 

  37. Lin C, Itti E, Haioun C, Petegnief Y, Luciani A, Dupuis J, et al. Early 18F-FDG PET for prediction of prognosis in patients with diffuse large B-cell lymphoma: SUV-based assessment versus visual analysis. J Nucl Med. 2007;48:1626–32.

    Article  PubMed  Google Scholar 

  38. Biggi A, Gallamini A, Chauvie S, Hutchings M, Kostakoglu L, Gregianin M, et al. International validation study for interim PET in ABVD-treated, advanced-stage Hodgkin lymphoma: interpretation criteria and concordance rate among reviewers. J Nucl Med. 2013;54:683–90.

    Article  CAS  PubMed  Google Scholar 

  39. Gallamini A, Barrington SF, Biggi A, Chauvie S, Kostakoglu L, Gregianin M, et al. The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale. Haematologica. 2014;99:1107–13.

    Article  PubMed Central  PubMed  Google Scholar 

  40. Hutchings M, Kostakoglu L, Zaucha JM, Malkowski B, Biggi A, Danielewicz I, et al. In vivo treatment sensitivity testing with positron emission tomography/computed tomography after one cycle of chemotherapy for Hodgkin lymphoma. J Clin Oncol. 2014;32:2705–11.

    Article  PubMed  Google Scholar 

  41. Itti E, Meignan M, Berriolo-Riedinger A, Biggi A, Cashen AF, Véra P, et al. An international confirmatory study of the prognostic value of early PET/CT in diffuse large B-cell lymphoma: comparison between Deauville criteria and DeltaSUVmax. Eur J Nucl Med Mol Imaging. 2013;40:1312–20.

    Article  PubMed  Google Scholar 

  42. Mamot CK, Renner C, Pabst T, Hitz F, Mey U, Pless M, et al. Final results of a prospective evaluation of the predictive value of interim PET in patients with DLBCL under R-CHOP14 (SAKK 38/07). Hematol Oncol. 2013;31 Suppl:96–150.

    Google Scholar 

  43. Dupuis J, Berriolo-Riedinger A, Julian A, Brice P, Tychyj-Pinel C, Tilly H, et al. Impact of [(18)F]fluorodeoxyglucose positron emission tomography response evaluation in patients with high-tumor burden follicular lymphoma treated with immunochemotherapy: a prospective study from the Groupe d’Etudes des Lymphomes de l’Adulte and GOELAMS. J Clin Oncol. 2012;30:4317–22.

    Article  CAS  PubMed  Google Scholar 

  44. Martelli M, Ceriani L, Zucca E, Zinzani PL, Ferreri AJ, Vitolo U, et al. [18F]fluorodeoxyglucose positron emission tomography predicts survival after chemoimmunotherapy for primary mediastinal large B-cell lymphoma: results of the International Extranodal Lymphoma Study Group IELSG-26 Study. J Clin Oncol. 2014;32:1769–75.

    Article  PubMed  Google Scholar 

  45. Trotman J, Luminari S, Boussetta S, Versari A, Dupuis J, Tychyj C, et al. Prognostic value of PET-CT after first-line therapy in patients with follicular lymphoma: a pooled analysis of central scan review in three multicentre studies. Lancet Haematol. 2014;1(1):e17–27.

    Article  Google Scholar 

  46. Raemaekers JM, Andre MP, Federico M, Girinsky T, Oumedaly R, Brusamolino E, et al. Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial. J Clin Oncol. 2014;32:1188–94.

    Article  PubMed  Google Scholar 

  47. Engert A, Haverkamp H, Kobe C, Markova J, Renner C, Ho A, et al. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin’s lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. Lancet. 2012;379:1791–9.

    Article  CAS  PubMed  Google Scholar 

  48. Radford J, Barrington S, Counsell N, Pettengell R, Johnson P, Wimperis J, et al. Involved field radiotherapy versus no further treatment in patients with clinical stages IA and IIA Hodgkin lymphoma and a ‘negative’ PET scan after 3 cycles ABVD. Results of the UK NCRI RAPID Trial. Blood (ASH Annual Meeting Abstracts). 2012;120:547.

    Google Scholar 

  49. Kobe C, Kuhnert G, Kahraman D, Haverkamp H, Eich HT, Franke M, et al. Assessment of tumor size reduction improves outcome prediction of positron emission tomography/computed tomography after chemotherapy in advanced-stage Hodgkin lymphoma. J Clin Oncol. 2014;32:1776–81.

    Article  PubMed  Google Scholar 

  50. Follows GA, Ardeshna KM, Barrington SF, Culligan DJ, Hoskin PJ, Linch D, et al. Guidelines for the first line management of classical Hodgkin lymphoma. Br J Haematol. 2014;166:34–49.

    Article  CAS  PubMed  Google Scholar 

  51. Itti E, Lin C, Dupuis J, Paone G, Capacchione D, Rahmouni A, et al. Prognostic value of interim 18F-FDG PET in patients with diffuse large B-Cell lymphoma: SUV-based assessment at 4 cycles of chemotherapy. J Nucl Med. 2009;50:527–33.

    Article  PubMed  Google Scholar 

  52. Casasnovas RO, Meignan M, Berriolo-Riedinger A, Bardet S, Julian A, Thieblemont C, et al. SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma. Blood. 2011;118:37–43.

    Article  CAS  PubMed  Google Scholar 

  53. Rossi C, Kanoun S, Berriolo-Riedinger A, Dygai-Cochet I, Humbert O, Legouge C, et al. Interim 18F-FDG PET SUVmax reduction is superior to visual analysis in predicting outcome early in Hodgkin lymphoma patients. J Nucl Med. 2014;55:569–73.

    Article  CAS  PubMed  Google Scholar 

  54. Duehrsen U, Hüttmann A, Müller S, Hertenstein B, Kotzerke J, Mesters R, et al. Positron emission tomography (PET) guided therapy of aggressive lymphomas – a randomized controlled trial comparing different treatment approaches based on interim PET results (PETAL Trial). Proceedings of the 56th ASH Annual Meeting, San Francisco, 6–9 December 2014. Abstract 391.

  55. Nols N, Mounier N, Bouazza S, Lhommel R, Costantini S, Vander Borght T, et al. Quantitative and qualitative analysis of metabolic response at interim positron emission tomography scan combined with international prognostic index is highly predictive of outcome in diffuse large B-cell lymphoma. Leuk Lymphoma. 2014;55:773–80.

    Article  CAS  PubMed  Google Scholar 

  56. Hasenclever D, Kurch L, Mauz-Korholz C, Elsner A, Georgi T, Wallace H, et al. qPET – a quantitative extension of the Deauville scale to assess response in interim FDG-PET scans in lymphoma. Eur J Nucl Med Mol Imaging. 2014;41:1301–8.

    Article  PubMed  Google Scholar 

  57. Lanic H, Mareschal S, Mechken F, Picquenot JM, Cornic M, Maingonnat C, et al. Interim positron emission tomography scan associated with international prognostic index and germinal center B cell-like signature as prognostic index in diffuse large B-cell lymphoma. Leuk Lymphoma. 2012;53:34–42.

    Article  CAS  PubMed  Google Scholar 

  58. Copie-Bergman CI, Moroch J, Safar V, Baia M, Dupuis J, Belhadj K, et al. BCL2 protein expression combined with early 18F FDG PET response allows improved stratification of large B-cell lymphoma patients (abstract). Hematol Oncol. 2013;31 Suppl 1:151–200.

  59. Gallamini A, Agostinelli C, Tripodo C, Starcqualursi L, Fuligni F, Fiore F, et al. Analysis of myeloid suppressor marker arginase identifies CD68+/arginase + myeloid/monocytic subsets and exerts stronger prognostic influence than macrophage quantification in classical Hodgkin lymphoma (abstract). Haematologica. 2013;98 Suppl 2:1–64.

    Google Scholar 

  60. Agostinelli C. A clinical-pathological algorithm based on the combination of interim PET with biological markers in classical Hodgkin lymphoma. Presented at the Fifth International Workshop on PET in Lymphoma, Menton, 19–20 September 2014. http://eitti.free.fr.

  61. Ganapathy-Kanniappan S, Geschwind JF. Tumor glycolysis as a target for cancer therapy: progress and prospects. Mol Cancer. 2013;12:152.

    Article  PubMed Central  PubMed  Google Scholar 

  62. Ma WW, Jacene H, Song D, Vilardell F, Messersmith WA, Laheru D, et al. [18F]fluorodeoxyglucose positron emission tomography correlates with Akt pathway activity but is not predictive of clinical outcome during mTOR inhibitor therapy. J Clin Oncol. 2009;27:2697–704.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  63. Su H, Bodenstein C, Dumont RA, Seimbille Y, Dubinett S, Phelps ME, et al. Monitoring tumor glucose utilization by positron emission tomography for the prediction of treatment response to epidermal growth factor receptor kinase inhibitors. Clin Cancer Res. 2006;12:5659–67.

    Article  CAS  PubMed  Google Scholar 

  64. Graf N, Li Z, Herrmann K, Weh D, Aichler M, Slawska J, et al. Positron emission tomographic monitoring of dual phosphatidylinositol-3-kinase and mTOR inhibition in anaplastic large cell lymphoma. Onco Targets Ther. 2014;7:789–98.

    PubMed Central  CAS  PubMed  Google Scholar 

  65. Lheureux S, Lecerf C, Briand M, Louis MH, Dutoit S, Jebahi A, et al. (18)F-FDG is a surrogate marker of therapy response and tumor recovery after drug withdrawal during treatment with a dual PI3K/mTOR inhibitor in a preclinical model of cisplatin-resistant ovarian cancer. Transl Oncol. 2013;6:586–95.

    Article  PubMed Central  PubMed  Google Scholar 

  66. Hudson CD, Hagemann T, Mather SJ, Avril N. Resistance to the tyrosine kinase inhibitor axitinib is associated with increased glucose metabolism in pancreatic adenocarcinoma. Cell Death Dis. 2014;5:e1160.

    Article  CAS  PubMed  Google Scholar 

  67. Prior JO, Montemurro M, Orcurto MV, Michielin O, Luthi F, Benhattar J, et al. Early prediction of response to sunitinib after imatinib failure by 18F-fluorodeoxyglucose positron emission tomography in patients with gastrointestinal stromal tumor. J Clin Oncol. 2009;27:439–45.

    Article  CAS  PubMed  Google Scholar 

  68. Ciunci CA, Perini RF, Avadhani AN, Kang HC, Sun W, Redlinger M, et al. Phase 1 and pharmacodynamic trial of everolimus in combination with cetuximab in patients with advanced cancer. Cancer. 2014;120:77–85.

    Article  CAS  PubMed  Google Scholar 

  69. Younes A. Novel agents targeting oncogenic pathways in lymphoma. In: Younes A, Coiffier B, editors. Lymphoma: diagnosis and treatment. Berlin: Springer; 2013, p. 363–370

    Chapter  Google Scholar 

  70. Gambacorti-Passerini C, Messa C, Pogliani EM. Crizotinib in anaplastic large-cell lymphoma. N Engl J Med. 2011;364:775–6.

    Article  PubMed  Google Scholar 

  71. Gambacorti Passerini C, Farina F, Stasia A, Redaelli S,Ceccon M,Mologni L,et al. Crizotinib in advanced, chemoresistant anaplastic lymphoma kinase-positive lymphoma patients. J Natl Cancer Inst. 2014;106:djt378.

    Article  PubMed  Google Scholar 

  72. Derenzini E, Lemoine M, Buglio D, Katayama H, Ji Y, Davis RE, et al. The JAK inhibitor AZD1480 regulates proliferation and immunity in Hodgkin lymphoma. Blood Cancer J. 2011;1(12):e46.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  73. Younes A. The rationale for combining targeted and biological anti-lymphoma drugs. Hematol Oncol. 2013;31:81–3.

    Article  PubMed  Google Scholar 

  74. Younes A, Hagenbeek A, Coiffier B. Optimising the lymphoma response criteria in the era of targeted therapy. Lancet Oncol. 2011;12:616–7.

    Article  PubMed  Google Scholar 

Download references

Conflicts of interest

None.

Author information

Authors and Affiliations

  1. LYSA Imaging, Department of Nuclear Medicine, Hôpitaux Universitaires Henri Mondor, Paris-Est Créteil University, Créteil, 94010, France

    Michel Meignan & Emmanuel Itti

  2. Research, Innovation and Statistic Department, Antoine Lacassagne Cancer Center, Nice University, Nice, France

    Andrea Gallamini

  3. Scientific Research Committee, S. Croce Hospital, Cuneo, Italy

    Andrea Gallamini

  4. Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA

    Anas Younes

Authors
  1. Michel Meignan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Emmanuel Itti
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Andrea Gallamini
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Anas Younes
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michel Meignan.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Meignan, M., Itti, E., Gallamini, A. et al. FDG PET/CT imaging as a biomarker in lymphoma. Eur J Nucl Med Mol Imaging 42, 623–633 (2015). https://doi.org/10.1007/s00259-014-2973-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-014-2973-6

Keywords

Search

Navigation